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Grb7 is an adapter protein that is involved in signalling pathways that mediate
eukaryotic cell proliferation and migration. Its overexpression in several cancer
types has implicated it in cancer progression and led to the development of the
G7-18NATE cyclic peptide inhibitor. Here, the preparation of crystals of
G7-18NATE in complex with its Grb7 SH2 domain target is reported. Crystals of
the complex were grown by the hanging-drop vapour-diffusion method using
PEG 3350 as the precipitant at room temperature. X-ray diffraction data were
collected from crystals to 2.4 A˚ resolution using synchrotron X-ray radiation
at 100 K. The diffraction was consistent with space group P21, with unit-cell
parameters a = 52.7, b= 79.1, c= 54.7 A˚, =  = 90.0, = 104.4. The structure of
the G7-18NATE peptide in complex with its target will facilitate the rational
development of Grb7-targeted cancer therapeutics.
1. Introduction
The human growth factor receptor-bound protein 7 (Grb7) is a
member of a family of adaptor proteins that include Grb10 and
Grb14, which act to couple activated tyrosine kinases to downstream
signalling pathways (Han et al., 2001). Grb7-family proteins share a
conserved multi-domain structure comprising of an N-terminal
proline-rich domain, a Ras-associating-like (RA) domain, a pleck-
strin homology (PH) domain, a region between the PH and SH2
termed the BPS domain and a C-terminal Src homology 2 (SH2)
domain (Han et al., 2001; Shen & Guan, 2004).
Upstream binding partners of Grb7 include focal adhesion kinases
(FAKs) and members of the ErbB receptor family. Grb7 is present in
focal adhesions, where it is bound and phosphorylated by FAK during
cell migration (Han & Guan, 1999, 2000). In the cytoplasm, Grb7
usually binds to the cytoplasmic domain of the ErbB-3 receptor;
however, studies have shown that in cancer cells Grb7 is associated
with the ErbB-2 receptor, which plays a major role in cancer cell
proliferation (Stein et al., 1994). Grb7 is overexpressed together with
ErbB-2 in breast cancer cell lines (Stein et al., 1994), as well as in
oesophageal and gastric carcinomas (Kishi et al., 1997; Tanaka et al.,
1997).
The C-terminal SH2 domain of Grb7 mediates its binding to its
interacting partners and forms the key recognition event necessary
for triggering the unwanted downstream effects when Grb7 is over-
expressed. SH2 domains are small modular domains which are able to
bind to phosphorylated tyrosines in a sequence-dependent manner
via a positively charged pocket on their surface (Bradshaw &
Waksman, 2002; Waksman et al., 1992) and recognize 3–6 residues
immediately C-terminal to the phosphotyrosine (referred to as Y + 1,
Y + 2 etc.) (Songyang et al., 1993). The Grb7 SH2 domain has a strong
preference for phosphotyrosines contained within a pYXN motif
(Pero et al., 2002) and forms a specific binding site for phospho-
tyrosines in the ErbB-2 receptor and FAK. The Grb7 SH2 domain is
thus a prime target for inhibition, as blocking its activity would
abolish the downstream effects of Grb7 when aberrantly over-
expressed.
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Using phage display, a nonphosphorylated peptide termed Grb7-
peptide18-no arms thioether (G7-18NATE) was developed and
found to be able to specifically bind to Grb7 SH2 and not to the
closely related Grb14 or Grb2 SH2 domains (Pero et al., 2002). Cell-
permeable G7-18NATE has been shown to be able to selectively
block the interaction of Grb7 and FAK in vivo, as well as to signifi-
cantly reduce pancreatic cell migration and the proliferation of
different breast cancer cell lines (Pero et al., 2007; Tanaka et al., 2006).
As phosphotyrosines are unstable and reduce cell-wall permeability,
the unphosphorylated G7-18NATE represents an attractive starting
point for targeting Grb7 in the treatment of cancer. NMR studies
have found that the G7-18NATE peptide has a tendency to form a
turn around the YXN motif, but is otherwise a highly flexible mole-
cule (Porter & Wilce, 2007).
To date, the structure of the Grb7 SH2 domain has been solved
using crystallography to 2.1 A˚ resolution (PDB entry 2qms; Porter et
al., 2007). This structure shows that the Grb7 SH2 peptide binding
site differs from other SH2 binding sites, with Ile522 blocking the Y+ 3
position, and explains the preferential binding of Grb7 SH2 to
G7-18NATE, which contains YXN in a turn confirmation (Porter et
al., 2007). Isothermal calorimetric experiments have been used to
determine that G7-18NATE binds to Grb7 SH2 with micromolar
affinity (Porter et al., 2007). It is remarkable that a peptide inhibitor
of this affinity displays cellular activity and suggests that a peptide
with improved affinity may possess an even more potent bioactivity.
In order to develop G7-18NATE-based peptides that possess
higher affinities for their target, we have undertaken crystallization of
the G7-18NATE–Grb7 SH2 complex. This is anticipated to reveal the
critical residues involved in the interaction and the structural basis for
this interaction. We thus report the preparation of the G7-18NATE
peptide in complex with the Grb7 SH2 domain and the formation
of diffracting crystals for structure determination using X-ray
crystallography.
2. Methods and results
2.1. Overexpression and purification of the Grb7 SH2 domain
The pGex2T plasmid containing the Grb7 SH2 insert (residues
415–532 of human Grb7) was obtained from Dr Roger Daly (Janes
et al., 1997). Grb7 SH2 was expressed as a GST-fusion protein in
Escherichia coli strain BL21 (DE3) plysS as described previously
(Porter et al., 2007). The overexpressed protein was isolated from the
cellular supernatant after incubation with glutathione beads (GE
Healthcare) overnight at 277 K. After washing the beads with wash
buffer (PBS pH 7.4, 0.5% Triton X-100 and 1 mM DTT), the fusion
protein was eluted off the beads with wash buffer containing 10 mM
glutathione. Grb7 SH2 was cleaved from the GST with a final con-
centration of 5 U ml1 thrombin (Sigma) overnight at 277 K. The
protein solution was dialysed against cation-exchange buffer [20 mM
N-(2-hydroxyethyl)piperazine-N-ethanesulfonic acid (HEPES) pH
7.6, 20% glycerol and 1 mM DTT] and applied onto a HiTrap SP
Sepharose XL cation-exchange column (GE Healthcare) equili-
brated in the same buffer. The Grb7 SH2 domain was eluted using a
linear gradient of 0–0.5M sodium chloride in cation-exchange buffer
over a volume of 20 ml. The semi-purified Grb7 SH2 domain was then
dialysed into 50 mM 2-morpholinoethanesulfonic acid (MES) pH 6.6,
100 mM NaCl and 1 mM DTT and further contaminants in the
protein solution were removed using a HiLoad 16/60 Superdex 75
column (GE Healthcare). The protein was then tested for purity
using a 15% SDS–PAGE gel and concentrated to 10 mg ml1 as
determined spectrophotometrically from the A280 using an extinction
coefficient of 8480M1.
2.2. G7-18NATE synthesis
The G7-18NATE peptide (amino-acid sequence WFEGYDNT-
FPC) was synthesized using standard solid-phase Fmoc chemistry
(Chan &White, 2000) using a Liberty Microwave Peptide Synthesizer
(CHEM corporation, Kamp-Lintfort, Germany) on a 0.1 mmol scale
of synthesis using Rink Amide Resin (Sewald & Jakubke, 2002). The
first residue was coupled manually. The required amount of Cys(tBu)
was dissolved in a threefold excess of 0.5M HBTU in synthetic grade
DMF. Diisopropyl ethylamine (DIPEA) was added to catalyse the
formation of the activated amino-acid ester. The preactivated Cys
ester mixture was then coupled to the dry swollen resin. The cysteine-
coupled resin was then transferred to a microwave peptide synthe-
sizer, upon which the full G7-18NATE sequence was assembled.
Difficult-to-couple amino acids such as Trp, Asn and Thr were double
coupled. The activator base was 2MDIPEA inN-methylpyrrolidone.
Deprotection after each coupling was effected with 20%(v/v) piper-
idine in DMF/0.1M HoBt (hydroxybenzotriazole). After the final
Fmoc deprotection, the N-terminal amino group on the tryptophan
was capped using a solution comprised of 171 mg chloroacetic acid
anhydride dissolved in 2 ml synthesis-grade DMF and 160 ml DIPEA
for 30 min at room temperature. After cleavage from the resin in TFA
and workup of the crude peptide, the potential CO2 adduct on the
tryptophan residue was removed using an adduct-removal reagent
composed of 10% acetic acid, 50% ACN/H2O and purified using
preparative RP-HPLC. The cyclization reaction was carried out in
100 mM NH4HCO3 adjusted to pH 8.00 and diluted with an equal
volume of 100% acetonitrile for 1 h at room temperature. Mass-
spectrometric analysis of the folded peptide confirmed the formation
of the thioether bond with the characteristic chloride-ion loss. The
folded peptide was repurified using preparative RP-HPLC and its
structure and purity were confirmed by mass spectrometry and
analytical RP-HPLC.
2.3. Complex formation and crystallization
G7-18NATE was added to Grb7 SH2 at a 2:1 molar ratio under
conditions previously shown by NMR spectroscopy to result in
complete complex formation in solution (Porter et al., 2007). Crys-
tallization screens were set up using a Honeybee crystallization robot
(Genomic Solutions) and 96-well Intelli-Plates (Art Robbins Indus-
tries) with drops consisting of 100 nl sample solution added to 100 nl
reservoir solution. The initial screens for crystallization conditions
were performed using commercially available kits from Sigma–
Aldrich, Hampton Research and Jena Bioscience. Crystals formed
within 2 d in condition Nos. 47, 82, 83, 84 and 98 of Index screen
(Hampton Research) at room temperature. These conditions were
optimized using the hanging-drop vapour-diffusion method, in which
1 ml protein/peptide solution was added to 1 ml reservoir buffer, and
crystals appeared in screens set up around condition Nos. 82, 83 and
84, all of which contained magnesium chloride in the reservoir buffer.
The crystals formed appeared to be small thin plates that were
stacked on each other. In order to try to slow the growth of the
crystals, 10%(w/v) glycerol was added to the reservoir buffer. Further
optimization was performed using Additive Screen (Hampton
Research), in which 0.2 ml additive solution was added to 0.9 ml
protein/peptide solution and 0.9 ml reservoir buffer. The final opti-
mized condition consisted of 17.5%(w/v) PEG 3350, 0.2M MgCl2,
0.1M glycine, 10%(w/v) glycerol and 0.1M bis-tris pH 6.0.
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2.4. Data collection
Diffraction data were collected at the Australian Synchrotron (to
2.4 A˚ resolution). A single crystal was picked up using a Hampton
cryoloop, streaked through a solution containing 25% glycerol in the
reservoir solution and flash-cooled at 100 K. X-ray diffraction data
were collected on the high-throughput protein crystallography
beamline at the Australian Synchrotron using an ADSC Quantum
210 detector. 91 diffraction images were recorded. The oscillation
angle for each frame was 1 and the exposure time was 1 s. The
diffraction data were integrated using MOSFLM (Leslie, 1999) and
the intensities were merged and scaled using SCALA (Collaborative
Computational Project, Number 4, 1994). Wilson scaling was applied
using TRUNCATE (Collaborative Computational Project, Number
4, 1994).
3. Results and discussion
The G7-18NATE peptide was synthesized and combined in a ratio of
2:1 (i.e. excess peptide) with the purified Grb7 SH2 domain at
10 mg ml1. This ratio was chosen in order to shift the equilibrium
towards the formation of 100% Grb7 SH2 domain in complex with
the peptide, at the risk of the excess peptide inhibiting crystal
formation. In addition, since the Grb7 SH2 domain–G7-18NATE
complex was highly soluble, it was important to undergo crystal-
lization trials at this high concentration. Dilution of the protein was
avoided by adding protein solution directly to the lyophilized and
pre-weighed peptide. No further purification of the complex was
undertaken as it was considered desirable to maintain excess peptide.
Crystallization conditions were obtained from standard screens and
were further optimized though the use of glycerol to slow down the
rate of crystal growth and through screening additives. The finding
that the optimum condition for crystallization was at pH 6.0 is con-
sistent with the pH-sensitivity of the interaction of the Grb7 SH2
domain with G7-18NATE. In a recent study, we determined a 100-
fold higher affinity of this interaction at pH 6.0 compared with pH 7.4
(Gunzburg et al., 2010).
The crystals grown under the optimized condition were plate-like
with dimensions of 0.01  0.06  0.1 mm (Fig. 1) and could be used
for the collection of high-quality diffraction data (Fig. 2) on the
Australian Synchrotron protein beamline (MX1). Diffraction data
are summarized in Table 1. The diffraction data were consistent with
space group P21. Starting phases have been found by molecular-
replacement techniques using Phaser (McCoy et al., 2007) and the
coordinate set previously determined in our laboratory for the Grb7
SH2 apo protein (PDB code 2qms). The electron density clearly
revealed the presence of the G7-18NATE peptide bound to each
Grb7 SH2 domain dimer and of four Grb7 SH2 domain molecules in
the asymmetric unit. Based upon the known molecular weight of the
Grb7 SH2–G7-18NATE complex of 15 089 Da, the presence of four
molecules in the asymmetric unit corresponds to a Matthews coeffi-
cient of 1.83 A˚3 Da1 and a solvent content of 32.76%.
The structure of the complex of the Grb7 SH2 domain with the
G7-18NATE inhibitor will provide valuable information as to the
basis of its affinity and specificity. In particular, it will be of interest
to compare the interaction of the G7-18NATE peptide with the Grb7
SH2 domain with the previously reported interaction of a phos-
phorylated peptide, representing a natural target peptide, with the
Grb7 SH2 domain solved using NMR spectroscopy (Ivancic et al.,
2003). The G7-18NATE inhibitor has already demonstrated bio-
logical activity in cancer cells despite its relatively low affinity for its
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Figure 1
Crystals of the Grb7 SH2–G7-18NATE complex of approximately 0.01  0.06 
0.1 mm in size.
Figure 2
A representative diffraction image acquired from a Grb7 SH2–G7-18NATE
complex crystal.
Table 1
Crystallographic data-collection statistics for the Grb7 SH2 –G7-18NATE complex.
Values in parentheses are for the highest resolution shell.
Space group P21
Unit-cell parameters (A˚, ) a = 52.7, b = 79.1, c = 54.7,
 = 90.0,  = 104.4,  = 90.0
Resolution (A˚) 37.42–2.41 (2.48–2.41)
No. of reflections 30241 (10904)
No. of unique reflections 15617 (1027)
Multiplicity 1.9 (1.9)
Completeness (%) 93.1 (84.3)
hI/(I)i 7 (2)
Rmerge† (%) 9.6 (43)
Rp.i.m.‡ (%) 9.4 (42)
† Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ, where Ii(hkl) is the intensity of
individual reflections. ‡ Rp.i.m. is the multiplicity-weighted Rmerge.
target (Pero et al., 2007; Tanaka et al., 2006). The structure of the
complex will play a key role in the discovery of second-generation
inhibitors of potentially high affinity for the Grb7 target and that are
more potently antitumorigenic.
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